{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Revlimid, Velcade, dexamethasone and Farydak","id":"OG000","title":"Arm 1 - RVD + Pan"},{"description":"Revlimid, Velcade and Dexamethasone","id":"OG001","title":"Arm 2 - RVD"}],"populationDescription":"The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.","reportingStatus":"POSTED","timeFrame":"From measurable response to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.","title":"Duration of Response","type":"SECONDARY"}